Soliqua is a once-daily injection that combines Lantus, or insulin glargine, with lixisenatide. The treatment is intended for adults with type 2 diabetes who cannot control their glycemic levels with basal insulin.
Paris, France-based Sanofi expects Soliqua to hit pharmacy shelves in January 2017.
More articles on supply chain:
6 latest FDA approvals
Bundled payments reach a turning point: Four strategies for success
Gartner names top 25 supply chains in healthcare
